Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Alterity Therapeutics has gained significant attention with their presentations at the International Congress of Parkinson’s Disease and Movement Disorders, highlighting the potential of their drug ATH434 as a disease-modifying treatment for Multiple System Atrophy (MSA). Interim Phase 2 data showed that ATH434 may stabilize clinical symptoms and biomarkers in MSA patients, with a subset of participants exhibiting stable or improved outcomes and no serious drug-related adverse events. The company is optimistic as they await further results from ongoing trials set to be released in 2025.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
